Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals — Q1 2017 Earnings Presentation

20 slides from Keryx Biopharmaceuticals's earnings presentation, May 4, 2017

  1. Slide 1: First Quarter 2017 Financial Results

    Keryx Biopharmaceuticals, Inc. First Quarter 2017 Financial Results May 4, 2017 Building a Leading Renal Company Exhibit 99.2

  2. Slide 2: Agenda – First Quarter 2017 Financial Results

    Agenda – First Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President and CEO 2017 Guidance & 1Q’17 Financial Results Scott Holmes, SVP and CFO Drivers of Recent Growth Tony Chambers, VP, Sales Vision & Future Growt

  3. Slide 3: Forward-looking Statements

    Forward-looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia, our 2017 financial guidance and the submission of an sNDA to the FDA to expand the label of ferric citrate to include the t

  4. Slide 4: Recent Business Highlights

    Reported ~15,800 prescriptions for 1Q’17 filled at pharmacies, a 72% increase compared to 1Q’16 Provided 2017 net U.S. Auryxia product sales guidance of $56 to $60 million Secured 95% unrestricted access to Auryxia for patients on phosphate binders across Medicare Part D and commercial; removes reim

  5. Slide 5: Financial Highlights

    Financial Highlights Scott Holmes SVP and Chief Financial Officer

  6. Slide 6: Guidance: 2017 Net U.S. Auryxia Product Sales

    Guidance: 2017 Net U.S. Auryxia Product Sales Providing 2017 Auryxia guidance of $56 to $60 million, based upon: Strong 1Q prescription demand and underlying trajectory Strong prescription growth as a result of increased breadth and depth of prescribing Impact of broad formulary access: 95% of phosp

  7. Slide 7: Strong 1Q 2017 Auryxia Prescription Demand

    Sources: IMS, Davita Rx, Fresenius Rx and Keryx data on file. Strong 1Q 2017 Auryxia Prescription Demand +72% IMS / Specialty mix Q1 2017: 55% / 45% prescriptions

  8. Slide 8: First Quarter 2017 Financial Highlights

    First Quarter 2017 Financial Highlights ($ in millions) 1Q 2017 (unaudited) 1Q 2016 (unaudited) Net U.S. Auryxia Product Sales $ 10.5 $ 5.6 License Revenue $ 1.3 $ 1.2 Total Revenue $ 11.8 $ 6.8 Cost of Goods Sold $ 4.3 $ 1.1 Operating Expenses* $ 29.9 $ 28.4 ($ in millions) March 31, 2017 (unaudite

  9. Slide 9: Drivers of Recent Growth

    Drivers of Recent Growth Tony Chambers Vice President Sales

  10. Slide 10: 1Q 2017 Growth in Dialysis Driven by Many Factors

    Increased breadth and depth of prescribing High level of brand awareness and growing clinical familiarity, with 50% more prescribers writing in 1Q’17 vs 1Q’16 Increased yield from our prescriber interactions, with 72% increase in prescriptions, including growth in number of new Auryxia patients Mean

  11. Slide 11: Future Growth Drivers & Vision

    Future Growth Drivers & Vision Greg Madison President and Chief Executive Officer

  12. Slide 12: Building a Leading Renal Company: Three Strategic Pathways

    Building a Leading Renal Company: Three Strategic Pathways Drive and Support Keryx’s Planned Growth GROW INSPIRE Maximize Auryxia’s Potential Grow in US dialysis market Launch & grow in US IDA, NDD- CKD market Expand Portfolio Build Keryx by adding strategic assets to our portfolio Manage Growth & T

  13. Slide 13: Near-Term Focus to Maximize Potential of Auryxia

    Near-Term Focus to Maximize Potential of Auryxia Significantly more dialysis patients could benefit from treatment with Auryxia Foundation PDUFA for expanded indication 11/6/17 Strong momentum in dialysis provides solid foundation for IDA opportunity Future Opportunity ~350,000 dialysis patients on

  14. Slide 14: Maximizing the Potential for Auryxia: IDA Opportunity

    Maximizing the Potential for Auryxia: IDA Opportunity Provides Significant Leverage 95 Renal Sales Specialists Same Physician Targets Cares for 450,000 dialysis patients Cares for 1.7 million pre-dialysis CKD patients Auryxia Conversations Auryxia Covered on all major Medicare Part D and Commercial

  15. Slide 15: IDA, NDD-CKD Program Overview

    Achievements: sNDA accepted; November 6, 2017 PDUFA target action date Completed Pivotal Phase 3 Trial: Demonstrated statistically significant differences versus placebo for the primary and all pre-specified secondary endpoints Comprehensive data of final results presented at ASN in November 2016 Ra

  16. Slide 16: Significant Opportunity Exists to Increase Number of People Treated

    Significant Opportunity Exists to Increase Number of People Treated with Auryxia ~ $2.2B Market ~$2.8B Market Market sizes are based on Auryxia dollars; Dialysis market size based on 350,000 patients, 6 tablets/day, $5.04 WAC/tablet, and a 42% gross to net adjustment. IDA near-term potential market

  17. Slide 17: Market Insights: Need Exists for Effective, Well Tolerated IDA Treatment

    Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment Goal: Position Auryxia as a new standard of care for the management of IDA in NDD-CKD Physician Perceptions of Current Treatment Options for IDA Oral Iron Convenient; widely available Nephrologists report low satisf

  18. Slide 18: Market Insights: Need Exists for Effective, Well Tolerated IDA Treatment

    Market Insights: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment Goal: Position Auryxia as a new standard of care for the management of IDA in NDD-CKD Physician Perceptions of Current Treatment Options for IDA Oral Iron Convenient; widely available Nephrologists report low satisf

  19. Slide 19: Key Takeaways

    Key Takeaways Strong first quarter 2017 growth supports $56 - $60 million in full year 2017 net U.S. Auryxia product sales Large unmet need in iron deficiency anemia; preparing for potential launch of Auryxia for expanded indication, pending approval in November 2017 Expanded indication would provid

  20. Slide 20: Keryx Biopharmaceuticals, Inc. First Quarter 2017 Financial Results

    Keryx Biopharmaceuticals, Inc. First Quarter 2017 Financial Results May 4, 2017 Building a Leading Renal Company

Keryx Biopharmaceuticals — Q1 2017 Earnings Presentation on 6ix